RECORDS ARE PUBLISHED REGULATORY ACTIONS. FIELDS THE ISSUING AUTHORITY DID NOT PUBLISH ARE MARKED AS NOT STATED, NEVER FILLED IN.
Drug Eye AfricaNational Actions, Continental Reach
Manufacturer profile

Biodeal Laboratories Ltd, Kenya

Every published regulatory action recorded against this manufacturer, across all African authorities Drug Eye Africa monitors. Built strictly from published regulatory decisions and nothing else.

What these numbers are. They are counts of published regulatory actions recorded on this register. They are not a finding about the company, not an allegation, and not a measure of product quality. A manufacturer appearing here has had actions published against named products by named authorities; the actions speak for themselves and each one links to its primary notice.
4
Recorded actions
1
Countries
1
Authorities
0
Class I actions recorded

Recorded actions

4 shown
ReferenceDateCtryProductBatchesActionClassSource
DEA-KE-2025-003407 Nov 2025KEIbuflam Plus Suspension
Biodeal Laboratories Ltd, Kenya
0424097 · 0824011RecallUnclassifiedTier 1 · Regulator-published
DEA-KE-2025-002215 Jul 2025KEPhenytoin Tablets
Biodeal Laboratories Ltd, Kenya
0724016RecallUnclassifiedTier 1 · Regulator-published
DEA-KE-2025-001903 Jun 2025KEIbuflam Plus Suspension
Biodeal Laboratories Ltd, Kenya
0623005RecallUnclassifiedTier 1 · Regulator-published
DEA-KE-2025-000407 Feb 2025KEAPC Tablets
Biodeal Laboratories Ltd, Kenya
1223038RecallUnclassifiedTier 1 · Regulator-published

Counts are of published regulatory actions recorded on this register. They are not a finding about the company, and this page says so.

Names as published

The issuing authorities published this name as: Biodeal Laboratories Ltd, Kenya.

Company response

No response filed. Any named company may register and publish a reply beside these records, and the invitation is logged whether or not it is answered.

How this page is built

  • Published regulator decisions only — no press reports, no allegations
  • Name matching is conservative: only corporate-form suffixes are stripped, and a name that would reduce to a single token is kept whole
  • Every action links to its primary notice